Edesa Biotech clinical trials we track

Check company identity source

Phase 2 / 3 1 trial

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of facial vitiligo that combines the extent of facial involvement and degree of depigmentation. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks. After: Measure: Mean percent change from baseline in F-VASI at Week 28 Description: The Facial Vitiligo Area Scoring Index (F-VASI) is a validated assessment of the extent and degree of depigmentation affecting the face with scores ranging from 0 to 3.5, where higher scores indicate greater facial vitiligo involvement. The primary endpoint is the mean percent change from baseline in F-VASI at Week 28. A greater reduction from baseline reflects greater improvement in facial vitiligo. Time frame: 28 Weeks.

Check registry source

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Mortality rate at Day 28 from IP administration. Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days. After: Measure: Mortality rate at Day 28 from IP administration. (Phase 2 and 3) Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 644 participants (planned). After: 278 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2024. After: 22 Jul 2024.

Recruitment status changed

Before: Suspended. After: Terminated.

Check registry source